Skip to main content
Investors
Media
open in a new window
Contact Us
open in a new window
|
Search
open in a new window
Company
Science & Medicine
Patients
Responsibility
Careers
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
Stock Information
Stock Quote & Chart
Historical Stock Quote
Analyst Coverage
Investor FAQs
IR Home
Why Invest
Events & Presentations
Corporate Governance
Governance Documents
Executive Management
Board of Directors
Committee Composition
Contact the Board
Financials
Quarterly Results
Annual Reports
SEC Filings
Press Releases
Investor Contacts
Investor Emails Alerts
RSS Feeds
Stock Information
Stock Quote & Chart
Historical Stock Quote
Analyst Coverage
Investor FAQs
Close
Close
Investors
Company
Product
Research & Development
Patients
Partnerships
Careers
Close
Press Releases
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
December 16, 2022
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
November 22, 2022
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 3, 2022
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
October 20, 2022
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
September 6, 2022
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
September 1, 2022
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
August 4, 2022
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
July 21, 2022
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
May 25, 2022
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
May 9, 2022
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
May 5, 2022
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
April 21, 2022
Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
March 2, 2022
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
February 17, 2022
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
February 3, 2022
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call
January 10, 2022
Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance
January 5, 2022
Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference